Solid Biosciences (SLDB) Net Cash Flow (2017 - 2026)

Solid Biosciences has reported Net Cash Flow for 10 years, with the latest figure at $236.6 million in Q1 2026.

• Quarterly Net Cash Flow rose 81.39% year-over-year to $236.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.8 million (down 7.89% YoY) and the FY2025 annual result came in at -$20.3 million, down 420.19% from the prior year.
• Net Cash Flow improved to $236.6 million in Q1 2026 per SLDB's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $236.6 million in Q1 2026 and troughed at -$77.6 million in Q3 2025.
• A 5-year average of $10.3 million and a median of -$1.4 million in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow surged 1035.32% in 2022, then plunged 670.37% in 2023.
• Over 5 years, Net Cash Flow stood at $106.4 million in 2022, then slumped by 76.51% to $25.0 million in 2023, then slumped by 36.5% to $15.9 million in 2024, then sank by 108.81% to -$1.4 million in 2025, then jumped by 17020.96% to $236.6 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $236.6 million, -$1.4 million, and -$77.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.